Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

11/13/24 6:44:33 PM ET

Medical Specialities

Health Care

Get the next $CSTL alert in real time by email

SC 13G/A 1 cstl1124.txt SCHEDULE 13G Amendment No. 5 Name of Issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 1,826,092 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 1,826,092 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 1,826,092 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 6.6% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Castle Biosciences Inc. Item l(b): Address of Issuer: 505 S Friendswood Drive, Ste 401, Friendswood, TX 77546 Item 2(a): Name of Person Filing: Wasatch Advisors LP Item 2(b): Address: 505 Wakara Way, Salt Lake City, UT 84108 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 14843C105 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 1,826,092 Item 4(b): Percent of Class Owned: 6.6% Item 4(c)(i): Sole Voting Power: 1,826,092 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 1,826,092 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [ ] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of September 30, 2024. Date: 11/13/24 Signature: /s/JB Taylor Name/Title: JB Taylor/CEO

Get the next $CSTL alert in real time by email

Date

Price Target

Rating

Analyst

12/14/2023

$25.00

Buy

Guggenheim

1/5/2023

$54.00

Sector Outperform

Scotiabank

1/7/2022

$59.00

Overweight

Stephens & Co.

11/9/2021

$85.00 → $75.00

Outperform

SVB Leerink

7/14/2021

$80.00 → $85.00

Outperform

SVB Leerink

Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

11/13/24 6:44:33 PM ET

$CSTL

Medical Specialities

Health Care

Get the next $CSTL alert in real time by email

Date

Price Target

Rating

Analyst

12/14/2023

$25.00

Buy

Guggenheim

1/5/2023

$54.00

Sector Outperform

Scotiabank

1/7/2022

$59.00

Overweight

Stephens & Co.

11/9/2021

$85.00 → $75.00

Outperform

SVB Leerink

7/14/2021

$80.00 → $85.00

Outperform

SVB Leerink

Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CSTL

Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CSTL

$CSTL
Insider Trading

Pres. & Chief Exec. Officer Maetzold Derek J sold $158,757 worth of shares (4,017 units at $39.52), decreasing direct ownership by 5% to 83,698 units (SEC Form 4)

Pres. & Chief Exec. Officer Maetzold Derek J sold $160,732 worth of shares (4,017 units at $40.01), decreasing direct ownership by 4% to 87,715 units (SEC Form 4)

Pres. & Chief Exec. Officer Maetzold Derek J was granted 62,219 shares, increasing direct ownership by 211% to 91,732 units (SEC Form 4)

$CSTL
Press Releases

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

$CSTL
SEC Filings

$CSTL
Analyst Ratings

SEC Form S-8 filed by Castle Biosciences Inc.

SEC Form 10-K filed by Castle Biosciences Inc.

Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Guggenheim initiated coverage on Castle Biosciences with a new price target

Scotiabank initiated coverage on Castle Biosciences with a new price target

Stephens & Co. initiated coverage on Castle Biosciences with a new price target

$CSTL
Financials

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Castle Biosciences Reports Third Quarter 2025 Results

$CSTL
Leadership Updates

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

$CSTL
Large Ownership Changes